Nothing Special   »   [go: up one dir, main page]

ZA200805599B - RNAI-mediated inhibition of Rho kinase for treatment of ocular hypertension/glaucoma - Google Patents

RNAI-mediated inhibition of Rho kinase for treatment of ocular hypertension/glaucoma

Info

Publication number
ZA200805599B
ZA200805599B ZA200805599A ZA200805599A ZA200805599B ZA 200805599 B ZA200805599 B ZA 200805599B ZA 200805599 A ZA200805599 A ZA 200805599A ZA 200805599 A ZA200805599 A ZA 200805599A ZA 200805599 B ZA200805599 B ZA 200805599B
Authority
ZA
South Africa
Prior art keywords
rnai
glaucoma
treatment
ocular hypertension
mediated inhibition
Prior art date
Application number
ZA200805599A
Other languages
English (en)
Inventor
Jon E Chatterton
Abbot F Clark
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA200805599B publication Critical patent/ZA200805599B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200805599A 2005-12-27 2006-12-19 RNAI-mediated inhibition of Rho kinase for treatment of ocular hypertension/glaucoma ZA200805599B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75409405P 2005-12-27 2005-12-27

Publications (1)

Publication Number Publication Date
ZA200805599B true ZA200805599B (en) 2009-11-25

Family

ID=38218805

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805599A ZA200805599B (en) 2005-12-27 2006-12-19 RNAI-mediated inhibition of Rho kinase for treatment of ocular hypertension/glaucoma

Country Status (14)

Country Link
US (4) US20070149473A1 (xx)
EP (2) EP2592144A1 (xx)
JP (2) JP2009532325A (xx)
KR (1) KR20080079264A (xx)
CN (1) CN101326285A (xx)
AR (1) AR057252A1 (xx)
AU (1) AU2006330606A1 (xx)
BR (1) BRPI0621264A2 (xx)
CA (2) CA2821393A1 (xx)
RU (2) RU2432165C2 (xx)
TW (1) TW200731979A (xx)
UY (1) UY30060A1 (xx)
WO (1) WO2007076367A2 (xx)
ZA (1) ZA200805599B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Rhoキナーゼ阻害剤
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
KR20100061792A (ko) * 2007-10-01 2010-06-09 알콘 리서치, 리미티드 안 질환을 치료 또는 예방하기 위한 간섭 rna 분자의 자기-상보적 aav 매개 전달
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
AR069328A1 (es) * 2007-11-15 2010-01-13 Alcon Mfg Ltd Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
TW200932274A (en) 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CN101643729B (zh) * 2008-08-07 2011-12-28 复旦大学 核酸分子nrn1sr22及其在制备抗癌药物中的应用
EP3354643B1 (en) 2009-05-01 2020-10-28 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
BR112013010525A2 (pt) * 2010-10-28 2016-08-02 Benitec Biopharma Ltd tratamento de hbv
CN102343091A (zh) * 2011-03-01 2012-02-08 中国科学技术大学 一种基于ezrin磷酸化的物质及其应用
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
WO2013103467A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
HUE061618T2 (hu) 2013-03-15 2023-07-28 Aerie Pharmaceuticals Inc Vegyület szemrendellenességek kezelésére
KR102579582B1 (ko) 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
CN111500538A (zh) * 2017-03-01 2020-08-07 中国科学院动物研究所 一种将非神经元细胞转化为神经元细胞的方法
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
JP2024535110A (ja) * 2021-09-30 2024-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Rhoグアニンヌクレオチド交換因子12(ARHGEF12)阻害剤による緑内障の治療
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525888A (en) * 2000-12-01 2006-04-28 Max Planck Gesellschaft RNA interference mediating small RNA molecules
US20050222029A1 (en) * 2001-01-04 2005-10-06 Myriad Genetics, Incorporated Compositions and methods for treating diseases
US20040115641A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20050019746A1 (en) * 2003-01-23 2005-01-27 Eirx Therapeutics Limited Apoptosis-related kinase/GPCRs
US20070054848A1 (en) * 2003-03-28 2007-03-08 Masaya Tohyama Composition and method for nerve regeneration
KR101471732B1 (ko) * 2003-08-27 2014-12-16 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
WO2005063983A1 (en) * 2003-12-29 2005-07-14 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2005085466A2 (en) * 2004-03-09 2005-09-15 Bayer Healtcare Ag Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005085469A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions

Also Published As

Publication number Publication date
UY30060A1 (es) 2007-04-30
US8168609B2 (en) 2012-05-01
JP2012193210A (ja) 2012-10-11
CA2821393A1 (en) 2007-07-05
US20120178794A1 (en) 2012-07-12
EP2592144A1 (en) 2013-05-15
KR20080079264A (ko) 2008-08-29
WO2007076367A3 (en) 2008-04-17
JP2009532325A (ja) 2009-09-10
RU2008130855A (ru) 2010-02-10
EP1989305A2 (en) 2008-11-12
AU2006330606A1 (en) 2007-07-05
CA2631840A1 (en) 2007-07-05
US20090275641A1 (en) 2009-11-05
US20070149473A1 (en) 2007-06-28
BRPI0621264A2 (pt) 2011-12-06
RU2011124528A (ru) 2012-12-27
RU2432165C2 (ru) 2011-10-27
WO2007076367A2 (en) 2007-07-05
AR057252A1 (es) 2007-11-21
TW200731979A (en) 2007-09-01
CN101326285A (zh) 2008-12-17
US20110245319A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
ZA200805599B (en) RNAI-mediated inhibition of Rho kinase for treatment of ocular hypertension/glaucoma
ZA200704932B (en) Rnai inhibition of CTGF for treatment of ocular disorders
WO2007059257A3 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
IL186598A0 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
EP2063882A4 (en) TYROSINKINASE INHIBITOR FOR PREVENTING OR TREATING INFECTIONS
HK1140827A1 (en) Ophthalmic lenses for prevention of myopia progression
EP1646614A4 (en) OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
HK1112718A1 (en) Aqueous ophthalmic suspension of crystalline rebamipide
IL178100A0 (en) 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
IL195152A0 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
ZA200900553B (en) Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions
EP1732484A4 (en) OPHTHALMIC IMPLANT FOR THE TREATMENT OF GLAUCOMA
WO2008036459A8 (en) Inhibitors of rho kinase
IL176141A0 (en) Crystalline forms of valacyclovir hydrochloride
IL207397A0 (en) Difluorobiphenylamide derivtives for the treatment of ocular hypertension
PL1905452T3 (pl) Środek do zapobiegania lub leczenia jaskry
IL198941A0 (en) Isosorbide mononitrate derivatives for the treatment of ocular hypertension
WO2007014250A8 (en) Abl kinase inhibition
EP1664011A4 (en) OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
IL188787A (en) Preparations for the treatment of diabetic eye complications
EP2032130A4 (en) OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF EYE HIGH PRESSURE
EP1890711A4 (en) COMPOUNDS FOR THE TREATMENT OR PREVENTION OF AMINOXIDASE-RELATED DISEASES OR DISEASES
ZA200706084B (en) RNAI-mediated inhibition of ocular hypertension targets
EP2299820A4 (en) OPHTHALMOLOGICAL FORMULATION OF RHO KINASE INHIBITOR COMPOUND